Skip to main content
Top
Published in: Pituitary 4/2013

01-12-2013

Cavernous sinus invasion might be a risk factor for apoplexy

Authors: Nese Cinar, Yasemin Tekinel, Selcuk Dagdelen, Hakan Oruckaptan, Figen Soylemezoglu, Tomris Erbas

Published in: Pituitary | Issue 4/2013

Login to get access

Abstract

The clinical features of pituitary hemorrhage vary from asymptomatic to catastrophic. We aimed to evaluate the frequency, symptoms, outcome and risk factors of clinical and subclinical pituitary apoplexy (PA) patients. In a retrospective analysis, charts of 547 pituitary adenoma patients from 2000 to December 2011 were reviewed. The patients were classified as clinical or subclinical PA. We compared the results with a control group without PA. Anterior pituitary hormones for endocrine dysfunction, histology, Ki-67 labeling index (LI), and p53 positivity of the tumor and pituitary imaging by magnetic resonance imaging were evaluated. Thirty-two patients (5.8 %) were diagnosed as clinical and 81 patients (14.8 %) as subclinical PA. Among PA patients, 85 patients (75.2 %) had a macroadenoma, 8 patients (7.1 %) had a microadenoma. The most frequent symptoms at presentation in PA patients were visual loss and headache. The patients with macroadenoma had a significantly increased risk for PA (p < 0.05). Hormone inactive tumors were significantly associated with the development of clinical PA (p = 0.05). Dopamine agonist use was significantly higher in subclinical PA patients (p = 0.001). Sex, Ki-67 LI, p53 positivity, diabetes mellitus, hypertension, somatostatin analogue and anticoagulant use did not predispose to PA whereas cavernous sinus invasion predisposed patients to PA (p < 0.01). The incidence of subclinical PA is higher than that of clinical PA. The development of PA is associated with macroadenomas. Clinically non-functioning tumors predispose to clinical PA. Cavernous sinus invasion of the tumor may be a sign of increased risk of bleeding.
Literature
1.
go back to reference Semple PL, Webb MK, de Villiers JC, Laws ER Jr (2005) Pituitary apoplexy. Neurosurgery 56(1), 65–72, discussion 72–63 (2005) Semple PL, Webb MK, de Villiers JC, Laws ER Jr (2005) Pituitary apoplexy. Neurosurgery 56(1), 65–72, discussion 72–63 (2005)
2.
go back to reference Findling JW, Tyrrell JB, Aron DC, Fitzgerald PA, Wilson CB, Forsham PH (1981) Silent pituitaryapoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 52(1):95–97PubMedCrossRef Findling JW, Tyrrell JB, Aron DC, Fitzgerald PA, Wilson CB, Forsham PH (1981) Silent pituitaryapoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 52(1):95–97PubMedCrossRef
3.
go back to reference Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51(2):181–188CrossRef Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51(2):181–188CrossRef
4.
go back to reference Onesti ST, Wisniewski T, Post KD (1990) Clinical versus subclinical pituitary apoplexy: presentation, surgical management, and outcome in 21 patients. Neurosurgery 26(6):980–986PubMedCrossRef Onesti ST, Wisniewski T, Post KD (1990) Clinical versus subclinical pituitary apoplexy: presentation, surgical management, and outcome in 21 patients. Neurosurgery 26(6):980–986PubMedCrossRef
5.
go back to reference Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120(3–4):118–122CrossRef Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120(3–4):118–122CrossRef
6.
go back to reference Biousse V, Newman NJ, Oyesiku NM (2001) Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry 71(4):542–545PubMedCrossRef Biousse V, Newman NJ, Oyesiku NM (2001) Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry 71(4):542–545PubMedCrossRef
7.
go back to reference Sibal L, Ball SG, Connolly V, James RA, Kane P, Kelly WF, Kendall-Taylor P, Mathias D, Perros P, Quinton R, Vaidya B (2004) Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary 7(3):157–163. doi:10.1007/s11102-005-1050-3 PubMedCrossRef Sibal L, Ball SG, Connolly V, James RA, Kane P, Kelly WF, Kendall-Taylor P, Mathias D, Perros P, Quinton R, Vaidya B (2004) Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary 7(3):157–163. doi:10.​1007/​s11102-005-1050-3 PubMedCrossRef
9.
go back to reference Lubina A, Olchovsky D, Berezin M, Ram Z, Hadani M, Shimon I (2005) Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir (Wien) 147(2):151–157, discussion 157. doi:10.1007/s00701-004-0413-2 Lubina A, Olchovsky D, Berezin M, Ram Z, Hadani M, Shimon I (2005) Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir (Wien) 147(2):151–157, discussion 157. doi:10.​1007/​s00701-004-0413-2
11.
go back to reference Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H (1984) Growth fractions in malignant non Hodgkin’s lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2(4):365–371PubMedCrossRef Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H (1984) Growth fractions in malignant non Hodgkin’s lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2(4):365–371PubMedCrossRef
12.
go back to reference Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20PubMedCrossRef Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20PubMedCrossRef
13.
go back to reference Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non secreting pituitary adenomas. Pituitary 1(3–4):213–220PubMedCrossRef Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non secreting pituitary adenomas. Pituitary 1(3–4):213–220PubMedCrossRef
16.
go back to reference Moller-Goede DL, Brandle M, Landau K, Bernays RL, Schmid C (2011) Pituitary apoplexy: re evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. Eur J Endocrinol 164(1):37–43. doi:10.1530/EJE-10-0651 PubMedCrossRef Moller-Goede DL, Brandle M, Landau K, Bernays RL, Schmid C (2011) Pituitary apoplexy: re evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. Eur J Endocrinol 164(1):37–43. doi:10.​1530/​EJE-10-0651 PubMedCrossRef
17.
go back to reference Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S, Jorgensen J, Kruse A, Laurberg P (2006) Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin Endocrinol (Oxf) 64(3):319–322. doi:10.1111/j.1365-2265.2006.02463.x CrossRef Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S, Jorgensen J, Kruse A, Laurberg P (2006) Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin Endocrinol (Oxf) 64(3):319–322. doi:10.​1111/​j.​1365-2265.​2006.​02463.​x CrossRef
20.
go back to reference da Motta LA, de Mello PA, de Lacerda CM, Neto AP, da Motta LD, Filho MF (1999) Pituitary apoplexy. Clinical course, endocrine evaluations and treatment analysis. J Neurosurg Sci 43(1):25–36PubMed da Motta LA, de Mello PA, de Lacerda CM, Neto AP, da Motta LD, Filho MF (1999) Pituitary apoplexy. Clinical course, endocrine evaluations and treatment analysis. J Neurosurg Sci 43(1):25–36PubMed
21.
go back to reference McFadzean R, Teasdale G (1996) Pituitary apoplexy. In: Landolt A, Vance M, Reilly P (eds) Pituitary adenomas. Churchill Livingstone, New York, NY, pp 485–501 McFadzean R, Teasdale G (1996) Pituitary apoplexy. In: Landolt A, Vance M, Reilly P (eds) Pituitary adenomas. Churchill Livingstone, New York, NY, pp 485–501
22.
23.
go back to reference Zayour DH, Selman WR, Arafah BM (2004) Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function. J Clin Endocrinol Metab 89(11):5649–5654. doi:10.1210/jc.2004-0884 PubMedCrossRef Zayour DH, Selman WR, Arafah BM (2004) Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function. J Clin Endocrinol Metab 89(11):5649–5654. doi:10.​1210/​jc.​2004-0884 PubMedCrossRef
24.
go back to reference Zhang X, Zhang W, Fu LA, Cheng JX, Liu BL, Cao WD, Fei Z, Zhang JN, Liu WP, Zhen HN (2011) Hemorrhagic pituitary macroadenoma: characteristics, endoscopic endonasal transsphenoidal surgery, and outcomes. Ann Surg Oncol 18(1):246–252. doi:10.1245/s10434-010-1243-5 PubMedCrossRef Zhang X, Zhang W, Fu LA, Cheng JX, Liu BL, Cao WD, Fei Z, Zhang JN, Liu WP, Zhen HN (2011) Hemorrhagic pituitary macroadenoma: characteristics, endoscopic endonasal transsphenoidal surgery, and outcomes. Ann Surg Oncol 18(1):246–252. doi:10.​1245/​s10434-010-1243-5 PubMedCrossRef
26.
go back to reference McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238–4244PubMedCrossRef McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238–4244PubMedCrossRef
27.
go back to reference Fahlbusch R, Buchfelder M (1988) Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien) 92(1–4):93–99CrossRef Fahlbusch R, Buchfelder M (1988) Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir (Wien) 92(1–4):93–99CrossRef
28.
go back to reference Wilson CB (1979) Neurosurgical management of large and invasive pituitary tumors. In: Tindall GT, Collins WF (eds) Clinical management of pituitary disorders. Raven, New York, NY, pp 335–342 Wilson CB (1979) Neurosurgical management of large and invasive pituitary tumors. In: Tindall GT, Collins WF (eds) Clinical management of pituitary disorders. Raven, New York, NY, pp 335–342
30.
go back to reference Bjerre P, Gyldensted C, Riishede J, Lindholm J (1982) The empty sella and pituitary adenomas. A theory on the causal relationship. Acta Neurol Scand 66(1):82–92PubMedCrossRef Bjerre P, Gyldensted C, Riishede J, Lindholm J (1982) The empty sella and pituitary adenomas. A theory on the causal relationship. Acta Neurol Scand 66(1):82–92PubMedCrossRef
31.
go back to reference Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI (2001) Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49(4):857–862, discussion 862–853 Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI (2001) Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49(4):857–862, discussion 862–853
32.
go back to reference Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumoto S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23(3):395–398PubMedCrossRef Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumoto S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23(3):395–398PubMedCrossRef
33.
go back to reference Pinto G, Zerah M, Trivin C, Brauner R (1998) Pituitary apoplexy in an adolescent with prolactin secreting adenoma. Horm Res 50(1):38–41PubMedCrossRef Pinto G, Zerah M, Trivin C, Brauner R (1998) Pituitary apoplexy in an adolescent with prolactin secreting adenoma. Horm Res 50(1):38–41PubMedCrossRef
Metadata
Title
Cavernous sinus invasion might be a risk factor for apoplexy
Authors
Nese Cinar
Yasemin Tekinel
Selcuk Dagdelen
Hakan Oruckaptan
Figen Soylemezoglu
Tomris Erbas
Publication date
01-12-2013
Publisher
Springer US
Published in
Pituitary / Issue 4/2013
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-012-0444-2

Other articles of this Issue 4/2013

Pituitary 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.